Laddar populära aktier...
Redeye provides its thoughts on the rights issue.
Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phase III study of mitazalimab in pancreatic...
Redeye discusses Alligator Bioscience's rights issue announced on 2 January.
Redeye comments on Alligator's sale of two bispecific antibodies to Orion, which were being developed by the latter under a licensing agreem...
Redeye comments on the new ALG.APV-527 phase I data.
Redeye comments on Alligator's Q3 report. The main event since our last update was the ALG.
Redeye comments on the positive ALG.APV-527 data presented at ESMO this weekend.
Redeye comments on Alligators Q2 report and updates its base case.
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a phase II study of mitazalimab combined wit...
Redeye comments on the start of a new phase I study of mitazalimab in local pancreatic cancer.
Redeye comments on Alligator Bioscience's Q1 report, including the sub-optimal funding situation after the rights issue and upcoming catalys...
Redeye comments on the outcome in the rights issue, with a subscription rate of 71%.
Redeye comments on the interim readout of the phase I study of ALG.
Redeye reviews Alligator Bioscience’s fourth quarter and the rights issue announced on Thursday evening.
Redeye increases its base case after the positive topline results from OPTIMIZE-1, the phase II study of mitazalimab in pancreatic cancer.
Redeye comments on Alligator’s CMD on 1 December, 2023.
Redeye comments on Alligator’s Q3 report. The OPTIMIZE-1 topline readout will be a major catalyst and is expected in early Q1 2024.
Redeye comments on the outcome of the TO6 warrants subscription.
Redeye has a positive view of mitazalimab obtaining orphan drug designation, which we discuss briefly.
Redeye is convinced by the second interim readout of mitazalimab in which the objective response rate was 44% based on 57 patients.
Redeye comments on the second interim readout with 57 evaluable patients.
Redeye comments on Alligator Bioscience following the rights issue and Q1 report.
Redeye resumes its coverage of Alligator following the rights issue adding SEK 181m (before transaction costs) to the company's balance shee...
Redeye gives a short comment on the announced rights issue and pauses its coverage.
Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing strong results (an ORR of 52%) in the int...
Redeye considers Mitazalimab’s results in the first interim readout of the phase II trial presented yesterday evening to be very promising, ...
Redeye comments on Alligator's announcement of the initiation of a second bispecific program within the Orion collaboration.
Redeye discusses events and financial results in Q3 2022.
Redeye comments on Alligator’s successful conclusion of the phase I trial with ATOR-1017.
Redeye comments on Alligator Bioscience’s second quarter report.
Redeye is optimistic about ATOR-1017 following new data released by Alligator Bioscience at ASCO 2022.
Redeye reevaluates Alligator Bioscience ahead of its first efficacy readout from mitazalimab later this year.
Redeye comments on Alligator Bioscience’s first quarter report.
Redeye finds it reassuring that mitazalimab is safe and tolerable at the highest dose tested in OPTIMIZE-1 in pancreatic cancer.
Redeye comments on Alligator Bioscience’s end-of-year report.
Redeye provides a brief comment on the news that Alligator is exploring financing alternatives.
Redeye comments on the research collaboration with Orion and sees a positive impact on our fair value estimate.
Redeye provides an initial take on Alligator’s Q2 report.